课题基金 / 基金详情

Copper-ionophores as a treatment for prostate cancer?

Copper-ionophores as a treatment for prostate cancer?
铜离子载体可以治疗前列腺癌吗?
批准号:
nhmrc : 1027125
负责人:
Dr Michael Cater
金额:
$20.95万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2012
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2012-01-01 至 2017-12-31

项目摘要

项目成果

Dr Michael Cater的其他基金

相似基金

相关文献

中文摘要
翻译
该项目的总体目标是评估前列腺癌的潜在治疗方法,其目标是该疾病的一个明显特征“铜含量升高”。我们实验室里的铜基药物选择性地破坏前列腺癌细胞而不伤害正常细胞。我们将验证这些药物是否在环境更复杂的体内起作用。这一原理的证明将开辟一个新的研究领域,并为前列腺癌提供一种新的治疗方法。
英文摘要
The overarching aim of this project is to evaluate a potential therapy for prostate cancer, which targets a distinct characteristic of the disease 'elevated copper'. Our copper-based drugs in the laboratory selectively destroy cancerous prostate cells without harming normal cells. We will verify whether these drugs work in the body where the environment is more complex. Proof of this principle will open up a new area of research and provide a novel therapeutic approach for prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neuronal copper homeostasis and the role of the Alzheimer Amyloid-Beta Precursor Protein (APP)
  • 批准号:
    nhmrc : 520345
  • 项目类别:
    Early Career Fellowships
  • 资助金额:
    $19.16万
  • 财政年份:
    2008
  • 负责人:
    Dr Michael Cater
  • 依托单位:
海外基金